ACM clears creation of proton-therapy joint venture

The Netherlands Authority for Consumer and Markets (ACM) has cleared the creation of ‘HollandPTC,’ a joint venture for proton therapy between TDH Services (part of Delft University of Technology), Erasmus Holding and Leiden University Medical Center. These parties will create a treatment and research facility for proton therapy. This type of therapy can be used to treat cancer.

ACM assessed in particular whether there are any anticompetitive risks associated with a collaboration between these parties with regard to health care services such as radio therapy. Based on an investigation and on discussions with a number of health insurers, this does not seem to be the case.

Proton therapy is currently not available in the Netherlands. It can be offered only after providers have been granted a license from the Dutch Minister of Health, Welfare and Sport, and after they have signed a contract with health insurers.